IPI-549
- Generic Name
- IPI-549
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H24N8O2
- CAS Number
- 1693758-51-8
- Unique Ingredient Identifier
- FOF5155FMZ
- Background
IPI-549 is under investigation in clinical trial NCT03795610 (Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma).
- Associated Conditions
- -
- Associated Therapies
- -
Renal Cancer Clinical Trial Pipeline Appears Robust With
DelveInsight's 'Renal Cancer Pipeline Insight 2024' report highlights a robust pipeline with 70+ companies developing 75+ therapies, including key players like Genentech and Merck. Promising drugs like Atezolizumab and ADI-270 are under various clinical trial phases, with recent FDA Fast Track designations for ADI-270 in metastatic RCC.
Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies
DelveInsight's 'Renal Cancer Pipeline Insight 2024' report highlights a robust pipeline with 70+ companies developing 75+ therapies, including key players like Genentech, Allogene Therapeutics, and Merck & Co. Inc. Promising therapies such as Atezolizumab and ALLO-316 are under various clinical trial phases, with recent FDA Fast Track designations and IND approvals for novel drugs like ADI-270 and AB-2100.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath